Oncology & Cancer

Will tarloxotinib finally break the HER2 barrier in lung cancer?

The HER2 gene is a well-known driver of breast cancer, where changes in this gene are found in about 1-in-5 cases of the disease. HER2 also contributes to about 3 percent of lung cancers, representing about 6,500 patients ...

Oncology & Cancer

Scientists create a complete atlas of lung tumor cells

Researchers from VIB, Leuven University and University Hospital Leuven studied thousands of healthy and cancerous lung cells to create the first comprehensive atlas of lung tumor cells. Their results reveal that tumors are ...

Oncology & Cancer

Two-pronged approach could curb many cases of lung cancer

Non-small-cell lung cancer, the most common type of lung cancer, is the leading cause of cancer death in the U.S. A new study suggests that about 1 in 4 cases, those driven by the KRAS oncogene, could be successfully treated ...

Oncology & Cancer

Making milestones against non-small cell lung cancer

Hard to detect in its early stages and hard to treat as it advances, lung cancer is the leading cause of cancer mortality around the world, with an estimated 1.6 million deaths each year. New treatments, however, are bettering ...

Immunology

The immune cells that help tumors instead of destroying them

Lung cancer is the leading cause of cancer-associated deaths. One of the most promising ways to treat it is by immunotherapy, a strategy that turns the patient's immune system against the tumor. In the past twenty years, ...

page 11 from 20